Engelborghs, S. et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol. Aging 29, 1143–1159 (2008).

Article  PubMed  Google Scholar 

Hampel, H. et al. Blood-based biomarkers for Alzheimer’s disease: current state and future use in a transformed global healthcare landscape. Neuron 111, 2781–2799 (2023).

Article  CAS  PubMed  Google Scholar 

Schindler, S. E. & Atri, A. The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer’s disease diagnostic revolution. Nat. Aging 3, 460–462 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Hansson, O. et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement. 18, 2669–2686 (2022).

Article  CAS  PubMed  Google Scholar 

Hansson, O., Blennow, K., Zetterberg, H. & Dage, J. Blood biomarkers for Alzheimer’s disease in clinical practice and trials. Nat. Aging 3, 506–519 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Mintun, M. A. et al. Donanemab in early Alzheimer’s disease. N. Engl. J. Med. 384, 1691–1704 (2021).

Article  CAS  PubMed  Google Scholar 

Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512–527 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leqembi. Prescribing Information. Eisai Inc. and Biogen. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269s000lbl.pdf (2023).

Aduhelm. Prescribing Information. Biogen and Eisai Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s003lbl.pdf (2021).

Cummings, J. & Fox, N. Defining disease modifying therapy for Alzheimer’s disease. J. Prev. Alzheimers Dis. 4, 109–115 (2017).

CAS  PubMed  PubMed Central  Google Scholar 

No Authors Listed. 2023 Alzheimer’s disease facts and figures. Alzheimers Dement. 19, 1598–1695 (2023).

Schindler, S. E. Fluid biomarkers in dementia diagnosis. Continuum 28, 822–833 (2022).

PubMed  Google Scholar 

Drabo, E. F. et al. Longitudinal analysis of dementia diagnosis and specialty care among racially diverse Medicare beneficiaries. Alzheimers Dement. 15, 1402–1411 (2019).

Article  PubMed  Google Scholar 

No Authors Listed. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 16, 391–460 (2020).

Article  Google Scholar 

Gauthier, S., Rosa-Neto, P., Morais, J. A. & Webster, C. World Alzheimer report 2021: journey through the diagnosis of dementia. Alzheimer’s Disease International. https://www.alzint.org/u/World-Alzheimer-Report-2021.pdf (2021).

Gauthier, S., Webster, C., Servaes, S., Morais, J. A. & Rosa-Neto, P. World Alzheimer Report 2022: life after diagnosis: navigating treatment, care and support. Alzheimer’s Disease International. https://www.alzint.org/resource/world-alzheimer-report-2022/ (2022).

Bradford, A., Kunik, M. E., Schulz, P., Williams, S. P. & Singh, H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis. Assoc. Disord. 23, 306–314 (2009).

Article  PubMed  PubMed Central  Google Scholar 

Rabinovici, G. D. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321, 1286–1294 (2019).

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization. Global Status Report on the Public Health Response to Dementia (2021).

HRSA. Health Resources and Services Administration, National Center for Health Workforce Analysis. Health Workforce Projections: Neurology Physicians and Physician Assistants. https://bhw.hrsa.gov/sites/default/files/bureau-health-workforce/data-research/bhw-factsheet-neurology.pdf (2017).

Bhattacharyya, D. S., Hossain, M. H., Dutta, G. K., Nowrin, I. & Saif-Ur-Rahman, K. M. Service coverage and health workforce allocation strategies for geriatric and palliative care in low- and middle-income countries: a protocol for a systematic review and meta-analysis. Medicine 101, e29030 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954–963 (2021).

Article  CAS  PubMed  Google Scholar 

Shaw, L. M. et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease. Alzheimers Dement. 14, 1505–1521 (2018).

Article  PubMed  Google Scholar 

Johnson, K. A. et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 9, e-1–e-16 (2013).

Article  Google Scholar 

Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 11, 669–678 (2012).

Article  CAS  PubMed  Google Scholar 

Mattsson-Carlgren, N. et al. Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology 98, e1137–e1150 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long, J. M. et al. Preclinical Alzheimer’s disease biomarkers accurately predict cognitive and neuropathological outcomes. Brain 145, 4506–4518 (2022).

Article  PubMed  PubMed Central  Google Scholar 

The Global CEO Initiative on Alzheimer’s Disease. UsAgainstAlzheimer’s. https://www.usagainstalzheimers.org/our-enterprise/CEOi (2024).

Amyvid. Prescribing information. Eli Lilly and Company. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202008s000lbl.pdf (2012).

Neuraceq. Prescribing information. Piramal Imaging S.A. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf (2014).

Vizamyl. Prescribing information. GE Healthcare. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203137s005lbl.pdf (2016).

Jack, C. R. Jr. et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).

Article  PubMed  Google Scholar 

Therriault, J. et al. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol. 80, 188–199 (2023).

Article  PubMed  Google Scholar 

Barthélemy, N. R. et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease. Nat. Aging 3, 391–401 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease. Nat. Med. 29, 1954–1963 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krishnadas, N., Villemagne, V. L., Doré, V. & Rowe, C. C. Advances in brain amyloid imaging. Semin. Nucl. Med. 51, 241–252 (2021).

Article  PubMed  Google Scholar 

Hardy-Sosa, A. et al. Diagnostic accuracy of blood-based biomarker panels: a systematic review. Front. Aging Neurosci. 14, 683689 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N. & Rubino, I. Diagnosis of early Alzheimer’s disease: clinical practice in 2021. J. Prev. Alzheimers Dis. 8, 371–386 (2021).

CAS  PubMed  Google Scholar 

Domingues, R., Bruniera, G., Brunale, F., Mangueira, C. & Senne, C. Lumbar puncture in patients using anticoagulants and antiplatelet agents. Arq. Neuropsiquiatr. 74, 679–686 (2016).

Article  PubMed  Google Scholar 

Bonomi, S., Gupta, M. R. & Schindler, S. E. Inadequate reimbursement for lumbar puncture is a potential barrier to accessing new Alzheimer’s disease treatments. Alzheimer’s Dement. 19, 5849–5851 (2023).

Article  Google Scholar 

Janelidze, S. et al. Plasma β-amyloid in Alzheimer’s disease and vascular disease. Sci. Rep. 6, 26801 (2016).

Article  CAS  PubMed